Health
FDA requires GLP-1 drugs to warn about potential vision loss risk.
NAION is an eye stroke that can cause sudden, permanent vision loss and has no proven treatment.
OriginalSourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedPublished00:09 UTCSourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedPublished00:09 UTC
“FDA warns of rare vision-loss side effect from GLP-1 drugs”
“The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands.”
FDA adds NAION risk warning to GLP-1 obesity/diabetes drugs
Key points
- FDA requires a warning for all GLP-1 drugs, including Ozempic and Wegovy.
- The eye condition NAION can cause partial or permanent vision loss.
- FDA analysis: roughly 6 in 100,000 GLP-1 users for at least one year affected.
- Placements of the warning followed a 2024 paper linking semaglutide to NAION.
- Experts urge monitoring symptoms and consulting a healthcare professional promptly.
Other reports
- SourceSTATUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at STATSourceSTATUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at STAT
“STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition”
- SourceMarketWatchUnited StatesOwner: Dow Jones & CompanyLeanCenterCredibilityRatings: AllSides, MBFCRead at MarketWatchSourceMarketWatchUnited StatesOwner: Dow Jones & CompanyLeanCenterCredibilityRatings: AllSides, MBFCRead at MarketWatch
“Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss”
- SourceQuartzUnited StatesLeanUnratedCredibilityUnratedRead at QuartzSourceQuartzUnited StatesLeanUnratedCredibilityUnratedRead at Quartz
“FDA is requiring weight loss drug makers to add a vision loss warning”
- SourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The IndependentSourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Independent
- SourceAP NewsUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at AP NewsSourceAP NewsUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at AP News
- SourceThe Washington PostUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Washington PostSourceThe Washington PostUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Washington Post
“FDA tells GLP-1 makers to warn of potential vision loss side effect”
- SourceNew York PostUnited StatesLeanCenter-rightCredibilityRatings: AllSides, MBFCRead at New York PostSourceNew York PostUnited StatesLeanCenter-rightCredibilityRatings: AllSides, MBFCRead at New York Post
“GLP-1 drugs must have new warning label over incurable blindness condition, says FDA”
- SourceGizmodoUnited StatesLeanUnratedCredibilityUnratedRead at GizmodoSourceGizmodoUnited StatesLeanUnratedCredibilityUnratedRead at Gizmodo
“FDA Orders New Vision Loss Warning for Ozempic and Other GLP-1s”
How it got here
CBS News publishes the article.
concise.news reads it.
Grouped with 8 other reports as story 9.
The Brief ranks it 9th.
9 9 FDA requires GLP-1 drugs to warn about potential vision loss risk.
NAION is an eye stroke that can cause sudden, permanent vision loss and has no proven treatment.